



HAL
open science

TOLL-LIKE RECEPTOR 4 D299G POLYMORPHISM AND INCIDENCE OF INFECTIONS IN CIRRHOTIC PATIENTS

Carlos Guarner-Argente, Elisabet Sánchez, Sílvia Vidal, Eva Román, Mar
Concepción, Maria Poca, Diego Sánchez, Cándido Juárez, Germán Soriano,
Carlos Guarner

► **To cite this version:**

Carlos Guarner-Argente, Elisabet Sánchez, Sílvia Vidal, Eva Román, Mar Concepción, et al..
TOLL-LIKE RECEPTOR 4 D299G POLYMORPHISM AND INCIDENCE OF INFECTIONS IN
CIRRHOTIC PATIENTS. *Alimentary Pharmacology and Therapeutics*, 2010, 31 (11), pp.1192.
10.1111/j.1365-2036.2010.04291.x . hal-00552544

HAL Id: hal-00552544

<https://hal.science/hal-00552544>

Submitted on 6 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**TOLL-LIKE RECEPTOR 4 D299G POLYMORPHISM AND
INCIDENCE OF INFECTIONS IN CIRRHOTIC PATIENTS**

Journal:	<i>Alimentary Pharmacology & Therapeutics</i>
Manuscript ID:	APT-0079-2010.R1
Manuscript Type:	Original Scientific Paper
Date Submitted by the Author:	04-Mar-2010
Complete List of Authors:	Guarner-Argente, Carlos; Hospital de la Santa Creu i Sant Pau, Department of Gastroenterology Sánchez, Elisabet; Hospital de la Santa Creu i Sant Pau, Department of Gastroenterology; CIBERehd Vidal, Sílvia; Hospital de la Santa Creu i Sant Pau, Department of Immunology Román, Eva; Hospital de la Santa Creu i Sant Pau, Department of Gastroenterology; CIBERehd Concepción, Mar; Hospital de la Santa Creu i Sant Pau, Department of Gastroenterology Poca, Maria; Hospital de la Santa Creu i Sant Pau, Department of Gastroenterology Sánchez, Diego; Hospital de la Santa Creu i Sant Pau, Department of Immunology Juárez, Cándido; Hospital de la Santa Creu i Sant Pau, Department of Immunology Soriano, Germán; Hospital de la Santa Creu i Sant Pau, Department of Gastroenterology; CIBERehd Guarner, Carlos; Hospital de la Santa Creu i Sant Pau, Department of Gastroenterology; CIBERehd
Keywords:	Cirrhosis < Hepatology, Hepatocellular carcinoma < Hepatology, Microbiology < Topics, Portal hypertension < Hepatology, Inflammation < Topics

1
2
3 TITLE PAGE
4
5
6
7

8 TITLE: TOLL-LIKE RECEPTOR 4 D299G POLYMORPHISM AND INCIDENCE
9
10 OF INFECTIONS IN CIRRHOTIC PATIENTS
11
12
13

14 RUNNING TITLE: TLR4 D299G POLYMORPHISM AND INFECTIONS IN
15
16 CIRRHOSIS
17
18
19

20
21
22 AUTHORS:
23

24 Carlos Guarner-Argente¹, Elisabet Sánchez^{1,2}, Silvia Vidal³, Eva Román^{1,2}, Mar
25
26 Concepción¹, María Poca¹, Diego Sánchez³, Cándido Juárez³, Germán Soriano^{1,2} and
27
28 Carlos Guarner^{1,2}
29
30
31
32

33
34 AFFILIATIONS:
35

36 ¹Department of Gastroenterology. ²Centro de Investigación Biomédica en Red de
37
38 Enfermedades Hepáticas y Digestivas (CIBERehd). ³Department of Immunology.
39
40 Hospital de la Santa Creu i Sant Pau. Barcelona. Spain.
41
42
43
44

45
46 CORRESPONDING AUTHOR:
47

48 Germán Soriano, MD
49

50 Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau
51

52 Mas Casanovas 90, 08041 Barcelona, Spain
53

54 e-mail: gsoriano@santpau.cat
55

56
57 telephone number: 34 93 5565920, FAX number: 34 93 556 5608
58
59
60

1
2
3 NUMBER OF TABLES: 3
4

5 NUMBER OF FIGURES: 0
6
7

8
9
10 ABBREVIATIONS:
11

12 TLR, toll-like receptor
13

14
15 PCR, protein chain reaction
16

17 RFLP, restriction fragment length polymorphism
18

19 PAMPS, pathogen-associated molecular patterns
20

21
22 NOD2, nucleotide-binding oligomerization domain containing 2
23

24 LPS, lipopolysaccharide
25

26 MD-2, myeloid differentiation protein 2
27

28 HIV, human immunodeficiency virus
29

30 SBP, spontaneous bacterial peritonitis
31

32 EDTA, ethylenediaminetetraacetic acid
33

34 bp, base pair
35

36
37 MELD, model for end stage liver disease
38

39
40 INR, international normalized ratio
41

42 GNB, gram-negative bacilli
43

44 GPC, gram-positive cocci
45
46
47
48
49

50 KEYWORDS: cirrhosis; bacterial infections; genetic polymorphisms; toll-like receptor
51

52
53 4.
54
55
56
57
58
59
60

SUMMARY

BACKGROUND. Toll-like receptor (TLR) 4 genetic polymorphisms, mainly D299G, have been associated with increased predisposition to infection in several populations.

AIM. To retrospectively analyze the relationship between the presence of the TLR4 D299G polymorphism and the incidence of bacterial infections in cirrhotic patients.

PATIENTS AND METHODS. We included 111 consecutive cirrhotic patients hospitalized with ascites and we determined the presence of the TLR4 D299G polymorphism by PCR-RFLP and its relationship with the incidence of previous bacterial infections. RESULTS. Ten out of 111 (9%) cirrhotic patients presented the TLR4 D299G polymorphism. The mean follow-up from first decompensation of cirrhosis until present admission was longer in D299G polymorphism patients than in wild type patients (53.8 ± 40.7 vs 35.4 ± 48.3 months, $p=0.03$). D299G polymorphism patients showed a trend towards a higher incidence of previous infections (80% vs 56.4%, $p=0.19$), as well as a higher number of infections (2.8 ± 2.3 vs 1.0 ± 1.3 , $p=0.01$) and bacteremias (0.4 ± 1.0 vs 0.04 ± 0.2 , $p=0.02$) per patient than wild type patients.

CONCLUSIONS. TLR4 D299G polymorphism could influence not only the predisposition to bacterial infections but also the evolution of the disease in cirrhotic patients. Further prospective studies in larger series of patients are warranted.

INTRODUCTION

Bacterial infections are a frequent and severe complication in cirrhosis, leading to significant morbidity and mortality^{1,2}. They are mainly caused by gram-negative bacilli, although gram-positive cocci are increasingly isolated due to antibiotic prophylaxis and instrumentation³. The predisposition of cirrhotic patients to develop bacterial infections is mainly the result of several alterations in the mechanisms of antimicrobial defence¹.

Most of these disturbances are due to liver insufficiency, portal hypertension and bacterial translocation^{1,2,4}. Mutations that alter the ability of innate immune receptors to bind to their pathogen-associated molecular patterns (PAMPS) may also affect host susceptibility to infection⁵⁻⁷. However, only one study has recently been published concerning the possible relationship between genetic factors and susceptibility to bacterial infections in cirrhotic patients⁸.

Toll-like receptors (TLR) are a family of transmembrane receptors with extracellular leucine-rich repeats and an intracellular signalling domain. They are found in monocytes, macrophages and neutrophils, and they function as receptors to recognize PAMPS, such as lipopolysaccharide (LPS), lipoproteins and peptidoglycans. They therefore play a key role in the innate immune response, inducing a signal that regulates the activation of several proinflammatory genes⁵⁻⁷.

In association with CD14 and its co-receptor MD-2, TLR4 triggers the inflammatory response to LPS of gram-negative bacteria, and is a key factor in eliciting the systemic inflammatory response that can lead to sepsis, organ failure, and septic shock^{5,6}. Two important non-synonymous TLR4 genetic polymorphisms have been described. One is an A/G polymorphism at rs4986790 that causes the change from Asp to Gly at aminoacid position 299 (D299G) and the other is a C/T polymorphism at rs4986791 that causes the change from Thr to Ile at position 399 (T399I). These polymorphisms are

usually found in cosegregation⁹ and have been shown to change the ligand-binding site of the receptor¹⁰ because they are located close to the TLR4-MD-2 binding areas.

These cosegregating TLR4 polymorphisms have been associated with blunted physiological responses to inhaled LPS⁹, an increased risk of gram-negative bacteremia in patients with sepsis^{11,12}, invasive aspergillosis in recipients of hematopoietic-cell transplants¹³, and with other infections such as malaria, brucellosis or candidiasis⁶. However, other studies do not confirm these associations^{5,6}. In addition, there are conflicting results about the functional impact of TLR4 (D299G and T399I) polymorphisms on the LPS-induced cytokine response¹⁴⁻¹⁶. These reports led us to explore the relevance of the TLR4 D299G polymorphism in cirrhotic patients, and analyze its frequency and relationship with the incidence of infections in this setting.

PATIENTS AND METHODS

All cirrhotic patients with ascites and previous episodes of decompensation (ascites, variceal bleeding, encephalopathy or infection) hospitalized in the Department of Gastroenterology from April 2006 to January 2009 were considered for inclusion in the study. Cirrhosis was diagnosed by biopsy or from clinical, analytical and ultrasonographic findings.

To minimize the effect of confounding factors in the development of bacterial infections or in the course of cirrhosis, we excluded patients with human immunodeficiency virus (HIV) infection or any other immunodeficiency, those with a permanent urinary catheter, and those with advanced hepatocellular carcinoma or any other condition that had determined poor short-term prognosis at first decompensation of cirrhosis. Finally, patients referred from other centres and those not fully controlled in our centre since

1
2
3 first decompensation of cirrhosis were also excluded to minimize the possibility of
4 missed infections.
5

6
7
8 We retrospectively determined the time of the first decompensation of cirrhosis (ascites,
9 variceal bleeding, encephalopathy or infection) and the period from this time until the
10 first day of the present hospitalization (study period). The length of the study period,
11 demographic, clinical and analytical characteristics and incidence of previous
12 complications were recorded at present hospitalization by patient interview and revision
13 of medical records. The incidence and the total number of infections during the study
14 period, the bacteria isolated and the type of infection were recorded by patient interview
15 and careful revision of medical records and the microbiology database. Spontaneous
16 bacterial peritonitis (SBP) was diagnosed on the basis of an ascitic fluid
17 polymorphonuclear cell count $\geq 250/\text{mm}^3$. Ascitic fluid was inoculated into blood
18 culture bottles for aerobic and anaerobic cultures at the bedside. A positive culture was
19 not considered necessary for diagnosis. Bacterascites was defined as the presence of a
20 positive culture of ascitic fluid with a polymorphonuclear count $< 250/\text{mm}^3$. Bacteremia
21 was diagnosed when blood culture was positive. If bacteremia was detected in the
22 course of a urinary tract infection, pneumonia, SBP or other infections, it was
23 considered secondary to these infections and was not recorded as a different infection.
24 Urinary tract infections were diagnosed on the basis of a positive urine culture.
25 Pneumonia, cellulitis and other infections were diagnosed using conventional criteria³.
26 Secondary bacterial peritonitis and postoperative wound infections were excluded from
27 the analysis, as TLR polymorphisms would be unlikely to influence the bacteria
28 responsible for these infections, and their inclusion could bias the results.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
60 Blood samples for later genetic analysis were obtained in the first day of the present
admission. Patients were classified into two groups: those with the TLR4 D299G

1
2
3 polymorphism (D299G group) and those without (wild type group). We compared the
4
5 demographic, clinical and analytical characteristics of patients and the incidence and
6
7 number of infections, according to the presence or absence of TLR4 D299G
8
9 polymorphism.
10
11

12 The study was approved by the Research Ethics Committee at Hospital de la Santa Creu
13
14 i Sant Pau. All patients gave consent to be included in the study after receiving
15
16 appropriate verbal and written information.
17
18
19

20 21 22 **Genomic DNA extraction and polymorphism genotyping**

23
24 Eight ml of peripheral blood was collected from each patient in EDTA-vacutainer tubes
25
26 and centrifuged at 2000 rpm for 10 minutes. Genomic DNA was extracted from buffy-
27
28 coat fraction using QIAmp DNA blood minikit (Qiagen®). The primer sequences used
29
30 for TLR4 Asp299Gly genotyping were 5'- GATTAGCATACTTAGA
31
32 CTACTACCTCCATG-3' and 5'-GATCAACTTCTGAAAAAGCATTCCCAC-3'. The
33
34 PCR consisted of an initial denaturation at 95°C for 3 minutes, followed by 34 cycles of
35
36 45 seconds at 95°C, 30 seconds at 57°C and 1 minute at 72°C, and a final extension of 5
37
38 minutes at 72°C. Once the amplification was confirmed, the PCR product was digested
39
40 for 1 hour at 37°C with restriction enzyme NcoI¹⁷.
41
42
43
44
45

46 The change of A to G at position 896 produced a site for the restriction enzyme NcoI.

47
48 The digested fragments of PCR amplification were analyzed by electrophoresis on 2.5%
49
50 agarosa gel. One band corresponding to a 190 base pair (bp) fragment was observed in
51
52 homozygous wild-type patients, two bands of 170 bp and 20 bp in patients homozygous
53
54 for the mutation, and three bands of 190 bp, 170 bp and 20 bp in heterozygous patients.
55
56
57
58
59
60

Statistical analysis

Data were expressed as mean±standard deviation or frequencies. Results were analyzed using the Chi² test with Yates correction and Fisher exact test for qualitative variables and Mann-Whitney test for quantitative parameters. Correlations were assessed by the Spearman test. A p value <0.05 was considered statistically significant. Statistical analysis was performed with the SPSS Statistical Package (version 17.0, SPSS Inc., Chicago, IL).

RESULTS

From April 2006 to January 2009, 192 cirrhotic patients with ascites were admitted to the Department of Gastroenterology and were considered for inclusion in the study. We excluded 4 patients with HIV infection, one patient with common variable immunodeficiency, 25 patients with advanced hepatocellular carcinoma or some other condition determining poor short-term prognosis at first decompensation (one severe cardiac failure, one ovarian neoplasia and one bladder neoplasia), 3 patients with a permanent urinary catheter, and 48 patients without previous decompensation of cirrhosis or referred from other institutions. Finally, 111 patients were included in the study.

The analysis of the TLR4 D299G polymorphism in this cohort of patients (n=111) revealed 10 were heterozygous patients (DG) (9%) and 101 were wild type (DD). None of the patients were homozygous for D299G (GG). The allelic frequency of this polymorphism was 0.045.

Patients' characteristics

Patients' clinical and analytical characteristics according to the presence or absence of the TLR4 D299G polymorphism are shown in Table 1.

We did not find statistical differences in demographic characteristics, etiology of cirrhosis, degree of liver insufficiency, presence of esophageal varices, previous complications of cirrhosis, previous prophylaxis with norfloxacin or beta-blockers, or ascitic fluid total protein levels. Serum creatinine was slightly but significantly higher in patients with TLR4 D299G polymorphism. Hepatic encephalopathy was more frequently the first decompensation of cirrhosis in patients with TLR4 D299G polymorphism than in wild type patients (20% vs 1.9%, $p=0.04$). Patients with the polymorphism also tended to present a higher incidence of hepatic encephalopathy during the study period (70% vs 37.6%, $p=0.08$).

The mean time from first decompensation of cirrhosis until blood was drawn for genetic analysis at present admission was 53.8 ± 40.7 months in patients with the TLR4 D299G polymorphism and 35.4 ± 48.3 in the wild type group ($p=0.03$). Considering only patients with cirrhosis caused by hepatitis C virus ($n=49$, 4 patients with TLR4 D299G polymorphism), mean time was 56.0 ± 35.4 and 33.8 ± 50.1 months, respectively ($p=0.09$).

Incidence and number of infections

The incidence and number of infections are shown in Table 2. A higher number of patients with the TLR4 D299G polymorphism had previous bacterial infections (8/10, 80% vs 57/101, 56.4%), infections caused by gram-negative bacilli and infections caused by gram-positive cocci than wild type patients, although these differences did not reach statistical significance. The number of infections per patient (2.8 ± 2.3 vs

1
2
3 1.0±1.3, p=0.01) was higher in the group with the TLR4 D299G polymorphism than in
4
5 the wild type group. The number of infections caused by gram-negative bacilli and the
6
7 number of those caused by gram-positive cocci were also higher in the former group;
8
9 these differences, however, only reached statistical significance for gram-positive cocci
10
11 infections (p=0.009).
12
13

14
15 Considering the different types of infections (Table 3), there was a trend towards a
16
17 higher incidence and number of infections per patient in the TLR4 D299G
18
19 polymorphism group for all the infection types (SBP, bacteremia, urinary infections,
20
21 pneumonia and cellulitis). These differences reached statistical significance for the
22
23 number of bacteremias per patient (0.4±1.0 vs 0.04±0.2, p=0.02) and the incidence of
24
25 bacteremia caused by gram-positive cocci (20% vs 1.9%, p=0.04).
26
27

28
29 There was no correlation between the number of infections and time from first
30
31 decompensation to the present admission (r=0.034, p=0.72).
32
33

34 35 36 **DISCUSSION**

37
38 To our knowledge, only one study evaluating whether genetic factors contribute to the
39
40 high risk for bacterial infections in cirrhotic patients has been published. The study of
41
42 Appenrodt et al⁸ has demonstrated an association between variants of NOD2
43
44 (nucleotide-binding oligomerization domain containing 2) linked to impaired mucosal
45
46 barrier function and the development of SBP and **mortality** in cirrhotic patients with
47
48 ascites.
49
50

51
52 In the present retrospective study, we observed a trend to a higher incidence of bacterial
53
54 infections and a significantly higher number of infections per patient in cirrhotic
55
56 patients with ascites and the TLR4 D299G polymorphism than in wild type patients.
57
58 These findings were similar for infections due to gram-negative bacilli and for those
59
60

1
2
3 caused by gram-positive cocci. Characteristics that could predispose patients to the
4 development of infections, such as the degree of liver insufficiency¹⁸, ascitic fluid total
5 protein levels^{19,20}, or prophylaxis with norfloxacin²¹⁻²³ or beta-blockers^{24,25} were similar
6
7
8
9
10 in the two groups. The longer evolution of disease since first decompensation in patients
11 with the D299G polymorphism could help to explain the higher number of infections in
12 these patients. There was no correlation, however, between the duration of this period
13 and the number of infections. Our findings therefore support the hypothesis that the
14 TLR4 D299G polymorphism could favour the development of infections in cirrhotic
15 patients.
16

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The higher number of infections caused by gram-positive cocci in patients with this polymorphism might be considered surprising, since TLR4 is mainly involved in the response to LPS from gram-negative bacteria⁵⁻⁸. One possible explanation is that a specific TLR polymorphism with a different sensitivity to its microbial ligand could decrease the basal innate immune tone involved in the general resistance to infection^{6,26-28}. This would be of special relevance in cirrhotic patients, as their immune system is frequently exposed to intestinal PAMPS due to bacterial translocation^{4,29,30}. Another explanation for this finding could be the presence of other TLR4-linked polymorphisms (e.g. TLR2, that binds to ligands from grampositive cocci)^{5,6} that were not determined in the present study.

We observed that the TLR4 D299G polymorphism was present in 9% of cirrhotic patients with ascites. As its frequency in non-cirrhotic populations is approximately 10%^{5,6,11-13,17,31}, our results suggest that the incidence of this polymorphism in cirrhotic patients is probably similar to that in the general population. We were unable to confirm this, however, as we did not have a control group to verify the incidence of the polymorphism in this population.

1
2
3 The incidence of encephalopathy as first decompensation was higher in TLR4 D299G
4 polymorphism patients than in wild type patients. In addition, this complication showed
5
6 a trend to a higher frequency during the study period in the former group.
7
8

9
10 Polymorphisms of glutaminase have recently been observed to increase the risk of
11
12 encephalopathy³². As the genes of glutaminase and TLR4 are located in different
13
14 chromosomes (2 and 9, respectively)^{31,33} it is unlikely that they cosegregate.
15
16

17 Inflammation is increasingly involved in the pathogenesis of hepatic encephalopathy³⁴.

18
19 It could therefore be that a different inflammatory response related to the presence of
20
21 the TLR4 D299G polymorphism favours the development of this complication. Finally,
22
23 the trend to a higher incidence of encephalopathy in patients with the polymorphism
24
25 could be a consequence of the higher number of infections in these patients^{1,2,4,34}. This
26
27 could also account for the higher serum creatinine levels in patients with the TLR4
28
29 D299G polymorphism, as they presented a tendency to a higher incidence of infections
30
31 as the cause of the present hospitalization^{1,2,23}.
32
33

34
35 Interestingly, the time period from first decompensation to present admission was
36
37 longer in TLR4 D299G polymorphism patients than in wild type patients. This
38
39 difference was more marked in patients with cirrhosis due to hepatitis C virus, but it did
40
41 not reach statistical significance. This finding, together with the fact that the degree of
42
43 liver insufficiency was similar in the two groups, could suggest a slower evolution of
44
45 cirrhosis in patients with the TLR4 D299G polymorphism. The inflammatory response
46
47 to PAMPS of intestinal origin seems to play a key role in the phenomena involved in
48
49 liver damage, hyperdynamic circulatory state and complications of portal hypertension
50
51 in cirrhosis^{4,7,29,30}. It could thus be hypothesized that the TLR4 D299G polymorphism
52
53 may induce a different immune response against PAMPS such as LPS and this could
54
55 account for a less severe evolution of the disease. It has recently been observed that the
56
57
58
59
60

1
2
3 presence of the TLR4 T399I and D299G polymorphisms decreases the risk of fibrosis in
4
5 patients with chronic hepatitis C³⁵⁻³⁷. This has been considered as likely due to a
6
7 reduction in TLR4-mediated inflammatory and fibrogenic signalling and a lower
8
9 apoptotic threshold of activated hepatic stellate cells³⁸. **Therefore, in addition to clinical,**
10
11 **analytical and hemodynamic parameters that have been shown to predict complications**
12
13 **and mortality in cirrhotic patients^{18-25,39-42}, genetic factors such as TLR polymorphisms**
14
15 **could influence the course of cirrhosis by modifying the inflammatory response.**

16
17
18
19
20 In spite of limitations regarding the low incidence of the TLR4 D299G polymorphism
21
22 and the retrospective nature of the study, our results suggest that genetic factors such as
23
24 TLR4 polymorphisms could influence not only predisposition and severity of bacterial
25
26 infections but also the evolution of the disease in cirrhotic patients. Further prospective
27
28 studies in larger series of patients are warranted and other genetic polymorphisms and
29
30 immunological mechanisms involved should be evaluated.
31
32
33

34 35 36 **ACKNOWLEDGEMENTS**

37
38 We thank Carolyn Newey for English language revision. This study was supported in
39
40 part by grant PS09/00357 from the Instituto de Salud Carlos III, Ministerio de Ciencia e
41
42 Innovación.
43
44
45

46
47
48 **FINANCIAL DISCLOSURE:** the authors do not have anything to disclose regarding
49
50 funding or conflict of interest with respect to this manuscript.
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. *Semin Liver Dis* 2008;28:26-42.
2. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. *Gut* 2005;54:718-725.
3. Fernández J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. *Hepatology* 2002;35:140-148.
4. Guarner C, Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. *Eur J Gastroenterol Hepatol* 2005;17:27-31.
5. Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. *Lancet Infect Dis* 2005;5:156-164.
6. Misch EA, Hawn TR. Toll-like receptor polymorphisms and susceptibility to human disease. *Clin Sci (Lond)* 2008;114:347-360.
7. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. *Gut* 2009;58:704-720.
8. Appenrodt B, Grünhage F, Gentemann MG, Thyssen L, Sauerbruch T, Lammert F. Nucleotide-binding oligomerization domain containing 2 (*NOD2*) variants are genetic risk factors for death and spontaneous bacterial peritonitis. *Hepatology* 2010;DOI 10.1002/hep.23440.
9. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. *Nat Genet* 2000;25:187-191.
10. Rallabhandi P, Bell J, Boukhvalova MS, et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. *J Immunol* 2006;177:322-332.

- 1
2
3 11. Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutations but
4 not CD14 polymorphisms are associated with an increased risk of gram-negative
5 infections. *J Infect Dis* 2002;186:1522-1525.
6
7
- 8
9
10 12. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4
11 receptor in patients with gram-negative septic shock. *Arch Intern Med* 2002;162:1028-
12 1032.
13
14
- 15
16
17 13. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and
18 aspergillosis in stem-cell transplantation. *N Engl J Med* 2008;359:1766-1777.
19
20
- 21
22 14. Dehus O, Bunk S, von Aulock S, Hermann C. IL-10 release requires stronger toll-
23 like receptor 4-triggering than TNF: a possible explanation for the selective effects of
24 heterozygous TLR4 polymorphism Asp(299)Gly on IL-10 release. *Immunobiology*
25 2008;213:621-627.
26
27
- 28
29
30 15. Erridge C, Stewart J, Poxton IR. Monocytes heterozygous for the Asp299Gly and
31 Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in
32 lipopolysaccharide signalling. *J Exp Med* 2003;197:1787-1791.
33
34
- 35
36
37 16. von Aulock S, Schroder NW, Gueinzus K, et al. Heterozygous toll-like receptor 4
38 polymorphism does not influence lipopolysaccharide-induced cytokine release in
39 human whole blood. *J Infect Dis* 2003;188:938-943.
40
41
- 42
43
44 17. Montes AH, Asensi V, Alvarez V, et al. The Toll-like receptor 4 (Asp299Gly)
45 polymorphism is a risk factor for Gram-negative and haematogenous osteomyelitis. *Clin*
46 *Exp Immunol* 2006;143:404-413.
47
48
- 49
50
51 18. Guarner C, Sola R, Soriano G, et al. Risk of a first community-acquired spontaneous
52 bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. *Gastroenterology*
53 1999;117:414-419.
54
55
56
57
58
59
60

- 1
2
3 19. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous
4 bacterial peritonitis. *Gastroenterology* 1986;91:1343-1346.
5
6
7
8 20. Such J, Guarner C, Enríquez J, Rodríguez JL, Serés I, Vilardell F. Low C3 in
9 cirrhotic ascites predisposes to spontaneous bacterial peritonitis. *J Hepatol* 1988;6:80-
10 84.
11
12
13
14
15 21. Soriano G, Guarner C, Tomás A, et al. Norfloxacin prevents bacterial infection in
16 cirrhotics with gastrointestinal hemorrhage. *Gastroenterology* 1992;103:1267-1272.
17
18
19
20 22. Saab S, Hernández JC, Chi AC, Tong MJ. Oral antibiotic prophylaxis reduces
21 spontaneous bacterial peritonitis occurrence and improves short-term survival in
22 cirrhosis: a meta-analysis. *Am J Gastroenterol* 2009;104:993-1001.
23
24
25
26
27 23. Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous
28 bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
29
30
31
32
33
34 24. González-Suárez B, Guarner C, Villanueva C, et al. Pharmacologic treatment of
35 portal hypertension in the prevention of community-acquired spontaneous bacterial
36 peritonitis. *Eur J Gastroenterol Hepatol* 2006;18:49-55.
37
38
39
40
41 25. Senzolo M, Cholongitas E, Burra P, et al. beta-Blockers protect against spontaneous
42 bacterial peritonitis in cirrhotic patients: a meta-analysis. *Liver Int* 2009;29:1189-1193.
43
44
45
46 26. Pamer EG. TLR polymorphisms and the risk of invasive fungal infections. *N Engl J*
47
48
49
50
51 27. Brandl K, Plitas G, Schnabl B, DeMatteo RP, Pamer EG. MyD88-mediated signals
52 induce the bactericidal lectin RegIII gamma and protect mice against intestinal *Listeria*
53
54
55
56
57
58 28. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and
59
60
atherogenesis. *N Engl J Med* 2002;347:185-192.

- 1
2
3 29. Francés R, Zapater P, González-Navajas JM, et al. Bacterial DNA in patients with
4
5 cirrhosis and noninfected ascites mimics the soluble immune response established in
6
7 patients with spontaneous bacterial peritonitis. *Hepatology* 2008;47: 978-985.
8
9
- 10 30. Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding
11
12 protein in cirrhotic patients with marked immune and hemodynamic derangement.
13
14 *Hepatology* 2003;37:208-217.
15
16
- 17 31. Schurmann M, Kwiatkowski R, Albrecht M, et al. Study of Toll-like receptor gene
18
19 loci in sarcoidosis. *Clin Exp Immunol* 2008;152:423-431.
20
21
- 22 32. Jover M, Galán E, Hoyas E, et al. Positional cloning in GLS gene: a microsatellite in
23
24 the promoter region predicts the risk of hepatic encephalopathy. *J Hepatol*
25
26 2009;50(suppl.1):S277(abstract).
27
28
- 29 33. Modi WS, Pollock DD, Mock BA, Banner C, Renauld JC, Van Snick J. Regional
30
31 localization of the human glutaminase (GLS) and interleukin-9 (IL9) genes by in situ
32
33 hybridization. *Cytogenet Cell Genet* 1991;57:114-116.
34
35
- 36 34. Córdoba J, Minguez B. Hepatic encephalopathy. *Semin Liver Dis* 2008;28:70-80.
37
38
- 39 35. Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of
40
41 developing cirrhosis in patients with chronic hepatitis C. *Hepatology* 2007;46:297-306.
42
43
- 44 36. Marcolongo M, Young B, Dal Pero F, et al. A seven-gene signatura (cirrosis risk
45
46 score) predicts liver fibrosis progresión in patients with initially mild chronic hepatitis
47
48 C. *Hepatology* 2009;50:1038-1044.
49
50
- 51 37. Li Y, Chang M, Abar O, Garcia V, et al. Multiple variants in toll-like receptor 4
52
53 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. *J*
54
55 *Hepatol* 2009;51:750-757.
56
57
58
59
60

1
2
3 38. Guo J, Loke J, Zheng F, et al. Functional linkage of cirrhosis-predictive single
4 nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses.
5
6 Hepatology 2009;49:960-968.
7
8

9
10 39. Chan CW, Tsochatzis EA, Carpenter JR, et al. Predicting the advent of ascites and
11 other complications in primary biliary cirrhosis : a staged model approach. Aliment
12 Pharmacol Ther 2010;31:573-582.
13
14
15

16
17 40. Somsouk M, Guy J, Biggins SW, et al. Ascites improves upon plus serum sodium
18 model for end-stage liver disease (MELD) for predicting mortality in patients with
19 advanced liver disease. Aliment Pharmacol Ther 2009;30:741-748.
20
21
22

23
24 41. Ripoll C, Groszmann R, García-Tsao G, et al. Hepatic venous pressure gradient
25 predicts clinical decompensation in patients with compensated cirrhosis.
26
27 Gastroenterology 2007;133:481-488.
28
29

30
31 42. Villanueva C, Aracil C, Colomo A, et al. Acute hemodynamic response to beta-
32 blockers and prediction of long-term outcome in primary prophylaxis of variceal
33 bleeding. Gastroenterology 2009;137:119-128.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TABLES

Table 1. Characteristics of patients with the TLR4 D299G polymorphism and wild type patients.

	D299G n=10	Wild Type n=101	p
Age (yr)	65.8±10.6	66.8±12.8	0.65
Sex (male/female)	6 (60)/4 (40)	57 (56.4)/44 (43.6)	1
Alcoholic etiology	4 (40)	38 (37.6)	1
Hepatitis C virus	4 (40)	45 (44.5)	1
Child-Pugh class, A/B/C	1 (10)/9(90)/0	14(13.8)/65(64.3)/ 22(21.7)	0.86
Child-Pugh score	8.1±1	8.2±1.5	0.86
MELD score	16.9±4.3	15.9±6.1	0.25
Serum sodium (mmol/L)	135.5±6.5	135.0±5.7	0.97
Urea (mmol/L)	10.5±4.8	11.2±11.7	0.63
Creatinine (µmol/L)	130.2±31.2	115.5±73.3	0.048
Albumin (g/L)	28.2±5.8	28.5±5.8	0.99
INR	1.4±0.2	1.5±0.7	0.64
Ascitic fluid total protein (g/L)	11.5±4.5	14.8±6.4	0.22
Previous ascites	10 (100)	101 (100)	1
Refractory ascites	4 (40)	31 (30.7)	0.72
Previous encephalopathy	7 (70)	38 (37.6)	0.08
Previous variceal bleeding	4 (40)	36 (35.6)	0.74
Hepatocellular carcinoma	1 (10)	18 (17.9)	0.75

Norfloxacin prophylaxis	2 (20)	8 (7.9)	0.22
Beta-blockers	6 (60)	47 (46.5)	0.51
Diuretics	5 (50)	76 (75.2)	0.13
Active alcoholism	2 (20)	22 (21.7)	1
Diabetes	4 (40)	42 (41.5)	1
First decompensation			
Ascites	6 (60)	71 (70.3)	0.49
Encephalopathy	2 (20)	2 (1.9)	0.04
Variceal bleeding	2 (20)	23 (22.8)	1
Infection	0	5 (4.9)	1
Cause of present admission			
Ascites	1 (10)	33 (32.6)	0.17
Encephalopathy	4 (40)	17 (16.8)	0.09
Variceal bleeding	0	8 (7.9)	1
Infection	4 (40)	21 (20.7)	0.22
Other	1 (10)	22 (21.7)	0.68

Data are mean±SD or frequency (%)

Table 2. Overall incidence, number of episodes and causative bacteria of previous infections in patients with the TLR4 D299G polymorphism and wild type patients.

	D299G n=10	Wild type n=101	p
Total infections			
Patients	8 (80)	57 (56.4)	0.19
Number of infections	28	103	
Number per patient	2.8±2.3	1.0±1.3	0.01
Infections caused by GNB ¹			
Patients	5 (50)	31 (30.6)	0.29
Number per patient	1.5±2.1	0.5±1.1	0.09
Infections caused by GPC ²			
Patients	5 (50)	21 (20.7)	0.05
Number per patient	1.1±1.2	0.2±0.4	0.009

Data are mean±SD or frequency (%)

¹GNB: gram-negative bacilli

²GPC: gram-positive cocci

Table 3. Type of previous infections in patients with the TLR4 D299G polymorphism and wild type patients.

	D299G n=10	Wild type n=101	p
SBP¹			
Patients	4 (40)	35 (34.6)	0.74
Number of SBP episodes	7	37	
Number per patient	0.7±1.2	0.3±0.5	0.60
Caused by GNB ²	1 (10)	9 (8.9)	1
Caused by GPC ³	2 (20)	9 (8.9)	0.26
Culture negative	2 (20)	18 (17.8)	1
Bacteremia			
Patients	2 (20)	4 (3.9)	0.09
Number of bacteremias	4	4	
Number per patient	0.4±1.0	0.04±0.2	0.02
Caused by GNB	1 (10)	2 (1.9)	0.25
Caused by GPC	2 (20)	2 (1.9)	0.04
Urinary infections			
Patients	4 (40)	25 (24.7)	0.28
Number of urinary infections	12	47	
Number per patient	1.2±2.1	0.4±1.1	0.22
Caused by GNB	3 (30)	21 (20.7)	0.45
Caused by GPC	1 (10)	7 (6.9)	0.54

Other infections			
Pneumonia	2 (20)	7 (6.9)	0.19
Bacterascites	0	3 (2.9)	1
Cellulitis	1 (10)	2 (1.9)	0.25
Secondary peritonitis	0	6 (5.9)	1

Data are mean±SD or frequency (%)

¹SBP: spontaneous bacterial peritonitis

²GNB: gram-negative bacilli

³GPC: gram-positive cocci